Korea’s Yuhan Corp. Has No Plans To Pursue Gilead’s Hep C Drug For Korea
This article was originally published in PharmAsia News
Executive Summary
Although Yuhan Corp. is gearing up to launch Gilead’s hepatitis B drug Viread, Gilead’s combination treatment is less attractive in Korea due to low marketability for HCV products.